BlueSphere Bio Accepted as Member of Johnson & Johnson Innovation-JLABS
August 14, 2024 10:15 ET
|
BlueSphere Bio
PITTSBURGH, Aug. 14, 2024 (GLOBE NEWSWIRE) -- BlueSphere Bio, a drug development company focused on the discovery of novel T-cell receptor (TCR) based therapies, announced it has been accepted as a...
BlueSphere Bio To Partner with NMDP BioTherapies℠ for the Company’s First-In-Human TCR-based Product Candidate in Combination with Allogeneic Hematopoietic Cell Transplantation Trial
June 25, 2024 10:00 ET
|
BlueSphere Bio
Through this partnership, BlueSphere will treat patients with acute myeloid and lymphocytic leukemia, and myeloid dysplastic syndrome, who have active disease or are at high risk for relapse, with the...
BlueSphere Bio Establishes Strategic Collaboration with the National Cancer Institute to Advance Treatments for Rare Respiratory Disease
June 04, 2024 10:00 ET
|
BlueSphere Bio
PITTSBURGH, June 04, 2024 (GLOBE NEWSWIRE) -- BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company utilizing a powerful TCR discovery platform to identify novel therapeutic candidates for...
BlueSphere Bio Announces IND Clearance of its First in Human Candidate and New Cell Therapy Portfolio for High-Risk Leukemia Patients
June 03, 2024 15:55 ET
|
BlueSphere Bio
TCX-101 Clinical Program: TCR T-Cell therapy product candidate (BSB-1001) to be delivered simultaneously with allogeneic stem cell transplant in patients with active disease or high risk of relapse ...
BlueSphere Bio to Present Corporate Update and Participate in a Panel Discussion at the 2024 BIO International Convention
May 30, 2024 10:00 ET
|
BlueSphere Bio
PITTSBURGH, May 30, 2024 (GLOBE NEWSWIRE) -- BlueSphere Bio, a drug development company focused on the discovery of novel T-cell receptor (TCR)-based therapies with a robust clinical pipeline and...
BlueSphere Bio to Present at the Next Generation CAR & T Cell Therapies Conference
March 01, 2023 10:17 ET
|
BlueSphere Bio
PITTSBURGH, Pa., March 01, 2023 (GLOBE NEWSWIRE) -- BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for...
BlueSphere Bio to Present at the 25th Annual BIO CEO & Investor Conference
February 06, 2023 10:17 ET
|
BlueSphere Bio
PITTSBURGH, Feb. 06, 2023 (GLOBE NEWSWIRE) -- BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for...
BlueSphere Bio Appoints Erkut Bahceci, M.D., as Chief Medical Officer
January 30, 2023 10:17 ET
|
BlueSphere Bio
Dr. Bahceci brings more than two decades of combined clinical and drug development experience PITTSBURGH, Pa., Jan. 30, 2023 (GLOBE NEWSWIRE) -- BlueSphere Bio, a T-cell receptor (TCR) T-cell...
BlueSphere Bio Presents Data Demonstrating the Potential of Lead Product Candidate at 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10, 2022 09:00 ET
|
BlueSphere Bio
BSB-1001 is the first product candidate from the TCX-101 platformData supports BSB-1001 as a potential treatment to improve outcomes for patients with acute myeloid leukemia (AML) receiving a...
BlueSphere Bio Data to be Presented at the 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 03, 2022 10:17 ET
|
BlueSphere Bio
PITTSBURGH, Nov. 03, 2022 (GLOBE NEWSWIRE) -- BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for...